Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
To establish efficacy and safety of HDM sublingual Immunotherapy (HDM-SLIT) by comparing Odactra and placebo, when given sublingually for 3 years to high risk infants aged between 6 to 12 months at enrollment in preventing the development of asthma, assessed 1.5 years after discontinuation of treatment.
Epistemonikos ID: bd8c357b11c770f8fc8228958751f1b637732817
First added on: May 09, 2024